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Abstract: Vascularization is a critical step in the restoration of cellular homeostasis. Several 41 
strategies including localized growth factor delivery, endothelial progenitor cells, genetically 42 
engineered cells, gene therapy, and pre-vascularized implants have been explored to promote 43 
re-vascularization. But, long-term stabilization of newly-induced vessels remains a challenge. 44 
It has been shown that fibroblasts and mesenchymal stem cells can stabilize newly-induced 45 
vessels. However, whether an injected biomaterial alone can serve as an instructive 46 
environment for angiogenesis remains to be elucidated. We report that appropriate vascular 47 
branching, and long-term stabilization can be promoted simply by implanting a hydrogel with 48 
stiffness matching that of fibrin clot. We have identified a unique sub-population of circulating 49 
CD11b+ myeloid and CD11b+/CD115+ monocytes that express the stretch activated cation 50 
channel Piezo-1 which is enriched prominently in the clot-like hydrogel. These findings offer 51 
evidence for a mechanobiology paradigm in angiogenesis involving an interplay between 52 
mechano-sensitive circulating cells and mechanics of tissue microenvironment.  53 
 54 
In peripheral artery disease, establishment of new vasculature is critical for rescuing the 55 
ischemic tissue and is a necessary step for successful engraftment of a transplanted 56 
tissue/organ. Therapeutic angiogenesis, is a clinical strategy pioneered by Takeshita and Isner, 57 
to induce new blood vessels (collateral vessels) in ischemic tissues from existing vasculature 58 
using external cues[1]. The repertoire of external cues range from localized delivery of 59 
proangiogenic factors (vascular endothelial growth factor (VEGF)[2], fibroblast growth 60 
factor(FGF)[3]), endothelial progenitor cells[4], cells genetically engineered to secrete a single 61 
or a combination of proangiogenic factors[5], and gene therapy[6]. More recently hypoxia-based 62 
strategies including pre-conditioning of mesenchymal stem cells (MSCs) to hypoxia before 63 
transplantation[7], and gene therapy to locally engineer cells to express hypoxia inducible 64 
factor-1a have also been explored. One of the challenges with local delivery of proangiogenic 65 
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signals, such as VEGF, is that the sprouting and maturation of new vessels into normal or 66 
aberrant (tumor-like vessels) depends on the formation of precise concentration gradients in 67 
the vessel microenvironment. These depend both on the combination of different isoforms with 68 
varying affinity for extracellular matrix and their local concentration[8], which are very difficult 69 
to modulate and control. After injury, endothelial cells (ECs) lose their quiescence and get 70 
primed and become sensitive to external pro-angiogenic cues. Maintenance of the 71 
neovasculature is however vital for vascular homeostasis. In this regard, perivascular cells i.e., 72 
pericytes and vascular smooth muscle cells play a critical role in vivo in not only providing 73 
scaffolding but also paracrine signaling necessary for blood vessel sprouting and maturation[9], 74 
In therapeutic angiogenesis, vessels often fail to mature and regress over time[10] due to 75 
inadequate recruitment of appropriate support cells, and it has been shown that co-culturing of 76 
ECs with MSCs[11] or fibroblasts[12] prior to implantation can promote stabilization of new 77 
blood vessels and their perfusion. Nonetheless, strategies to promote maturation and 78 
stabilization of neovasculature through endogenous mechanisms could be more translatable.  79 
 80 
During angiogenesis, ECs express av family of integrins, which are transmembrane proteins 81 
that specifically bind to the arginine-glycine-aspartic acid (RGD) sequence found in many 82 
ECM molecules including collagen, fibronectin, and vitronectin[13]. Since integrins are also 83 
anchored to the actin cytoskeleton of the cell[14], they function as mechanotransducers and 84 
assist the cells in perceiving the mechanics of the ECM; and it has been shown that integrin 85 
signaling is necessary for both EC survival and proliferation[15]. In spite of this compelling 86 
evidence linking mechanical cues to EC function, the impact of the ECM mechanical properties 87 
on blood vessel sprouting and maturation remains unknown. We had recently demonstrated in 88 
vitro that soft carboxylated agarose (CA) hydrogel in combination with RGD-signaling and 89 
soluble pro-angiogenic signals (VEGF, FGF-2 and phorbol-12-myristate 13-acetate (PMA)) 90 
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can promote the apical-basal polarization of ECs and their organization into free-standing 91 
multicellular lumens[16]. Encouraged by this observation, in this study we inquired if the mere 92 
introduction of CA hydrogels of appropriate mechanical properties could be sufficient to 93 
promote maturation and stabilization of neovasculature in vivo. Specifically, we chose a 2 % 94 
w/v solution of CA with 28% and 60% carboxylation as they yielded gels of two distinct 95 
stiffness (5 kPa (stiff gel) and 0.5 kPa (soft gel), respectively) that mimic the mechanical 96 
properties of gastrocnemius lateralis muscle, which has been reported be around to around 11 97 
kPa which corresponds to a shear modulus of around 3-4 kPa [17], and fibrin network of blood 98 
clot (0.06 – 0.6 kPa)[18]. To ensure mechanical coupling of ECs with the gel and to exploit the 99 
known benefits of RGD signaling in maintenance of EC function, the CA backbone was 100 
functionalized with a peptide presenting the GGGGRGDSP sequence in the N-terminus using 101 
aqueous 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry, as previously 102 
described[16]. Since RGD ligand density is known to impact cell-biomaterial interaction, the 103 
reaction conditions were optimized to ensure the same density of RGD (11.6±0.9 % of 104 
disaccharide repeat units) in both CA gels.  105 
 106 
Mechanically-defined carboxylated agarose hydrogels support vascular ingrowth and 107 
recruitment of mural cells:  108 
In order to evaluate the potential angiogenic response of CA hydrogels, four formulations: soft 109 
and stiff gels with and without soluble growth factors supplementation (GFs: 2.5 ng/mL of 110 
each VEGF, FGF-2 and PMA, i.e. 0.125 ng of each/50 µL of gel injected in the muscle) were 111 
implanted into SCID mice gastrocnemius muscles, a target tissue relevant for peripheral artery 112 
diseases. The concentration of the growth factors in this cocktail was based on our previous 113 
finding that they can promote organization of endothelial cells into lumens in vitro[16]. 114 
Hematoxylin and Eosin staining revealed that after 2 weeks, gels were evident in all conditions 115 
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and invoked no adverse inflammatory response or foreign-body reaction with collagenous 116 
capsule formation, and thus were well tolerated by the muscle tissue (Figure 1a-d). The ability 117 
of the CA gels to support the ingrowth of micro-vessels into its avascular environment was 118 
investigated by immunofluorescence and confocal microscopy. All CA gel environments, 119 
irrespective of GF supplementation were efficiently invaded by newly formed micro-vessels, 120 
physiologically associated with mural cells, i.e. pericytes (positive for nerve/glial antigen 2 121 
(NG2) and negative for a-SMA), and smooth muscle cells (positive for a-SMA) (Figure 1e-122 
h). The vessel diameters (Figure 1i) were similar in all conditions and the degree of 123 
angiogenesis within the gel as measured by the vessel length density (VLD), i.e. the total length 124 
of vessels in a given area, was statistically similar between soft and stiff gel formulations 125 
regardless of GF supplementation (stiff vs soft and stiff +GF vs soft +GF) (Figure 1j). It is 126 
well established that functionality of micro-vascular networks correlates with branching (short 127 
segment length, which depends on the number of branch points in relation to the total amount 128 
of vascularity)[19] and a moderate diameter in the range of capillaries (5-10 µm). In this regard, 129 
the shortest average segment length interestingly was achieved in the soft gel environment in 130 
absence of GF, while in their presence segment length was the highest of all conditions, though 131 
not statistically significant (soft = 207.8±48.2 µm, soft+GF = 428.5±103.6 µm, stiff = 132 
277.1±41.3 µm, stiff+GF = 278.5±55.6 µm, p<0.01 soft vs stiff, p<0.05 soft vs stiff+GF and 133 
p=0.087 soft vs soft+GF) (Figure 1k). In order to assess if the capacity of CA gels to support 134 
vascular ingrowth could be further improved, CA gels were supplemented with Matrigel (0.01 135 
% w/v), a biomaterial known to stimulate angiogenesis due to its optimal combination of basal 136 
lamina extracellular matrix and rich content of natural angiogenic growth factors[20]. The 137 
choice of the Matrigel concentration was based on our prior studies showing that at this 138 
concentration, Matrigel can support EC tubular organization while having no impact on the 139 
mechanical properties of the CA gel[16]. After two weeks, we found that Matrigel addition did 140 
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not affect the integration of the gels in the muscle and did not confer any noticeable benefits 141 
over CA gels supplemented with GF and yielded capillary networks that were less branched, 142 
as evidenced by longer vascular segments (Figure S1a-g). Taken together, these data suggest 143 
that while both soft and stiff gels were equally effective in inducing initial vascular ingrowth, 144 
the addition of growth factors or Matrigel does not confer any significant advantage, but the 145 
gel stiffness appears to matter for vessel branching. 146 
 147 
Microenvironment with mechanical properties similar to blood clot uniquely promotes 148 
long-term stabilization and patency of newly formed vascular structures:  To be 149 
therapeutically useful, newly induced vascular structures must stabilize, i.e. persist long-term 150 
without regression. Since, newly induced vessels require about 4 weeks to become independent 151 
of further angiogenic stimuli and persist indefinitely[8], the fate of initially induced vascular 152 
structures (vasculature diameter, length density and branching) within CA gels with and 153 
without GF was characterized 7 weeks after implantation (Figure 2a-d). Since GF and Matrigel 154 
supplementation yielded similar outcomes, the condition with GF alone was included in this 155 
experiment in order to account for their role during initial vessel induction. 156 
We made a compelling finding that although vessel diameter was similar among all groups 157 
(Figure 2i), vasculature within the stiff gels in the absence of GF showed a significant 158 
regression of 50 % of VLD when compared to the 2-week time point from 3.4±0.3 to 1.7±0.2 159 
mm/mm2 (p<0.0001) (Figure 2j). In contrast, within soft gels similarly deprived of GF not 160 
only was the vessel regression arrested, but a further 125% expansion of the vessel network 161 
was observed (VLD 2wk = 3.6±0.3 mm/mm2, p<0.0001 vs 7wk = 8.1±1.3 mm/mm2) resulting 162 
in considerably denser vascularity than within the stiffer gels (Figure 2a-h). Further analysis 163 
revealed that within the stiff gels vessel regression was accompanied by a reduction in network 164 
branching, with a 40% increase in vascular segment length from 277.1±41.3 µm to 465.2±73.7 165 
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µm; whereas within the soft gels capillary networks further increased their branching degree 166 
compared to the 2-week time-point regardless of GF supplementation (segment length soft = 167 
117.4±10.5 µm and soft +GF = 55.3±18.5 µm) (Figure 2k). Once again as in the case at 2 168 
weeks GF supplementation neither increased vessel density within soft gels nor did it promote 169 
stabilization (VLD 7wk soft+GF = 7.2±1.5 mm/mm2 vs soft = 8.1±1.3 mm/mm2, p = n.s.; VLD 170 
2wk soft+GF = 5.0±0.8 mm/mm2 vs soft = 4.7±0.3 mm/mm2, p = n.s.). Pericytes have been 171 
shown to play a crucial role in vessel stabilization, both through secreted and cell contact-172 
dependent signals [21]. While vessels within the stiff gels were scarcely associated with mural 173 
cells of any kind (Figure 2a-b and e-f), vessel networks within the soft gels resembled normal 174 
muscle capillaries and were associated with NG2+ pericytes (Figure 2c-d), which established 175 
tight cell-to-cell contacts with the endothelium (Figure 2g-h). Quantification of pericyte 176 
coverage (ratio of vessel length associated with NG2+ pericytes/total vessel length) showed 177 
that vascular networks within the soft gels were greater than 5-fold more mature compared to 178 
those within the stiff gels (soft+GF = 0.76±0.08 vs stiff+GF = 0.13±0.03, p<0.001; and soft = 179 
0.73±0.05 vs stiff = 0.14±0.02, p<0.01; Figure 2q). Considering the large body of work 180 
highlighting the challenges associated in controlling complex set of variables (i.e., dose 181 
distribution in tissue, duration of stimulation, growth factor splice variants and their 182 
combinations) that impact the induction of physiological angiogenesis by growth factor 183 
delivery (either as delivered proteins or by gene therapy)[8, 22, 23], the ability of a mechanically 184 
defined biomaterial environment to induce robust and persistent normal angiogenesis 185 
independently of growth factor delivery, as shown here, is particularly attractive. 186 
 187 
Newly formed vessels require functional perfusion by the systemic circulation in order to 188 
stabilize and persist, as lack of flow in a nascent vascular structures, regulated by pre-capillary 189 
arteriole sphincters, is a mechanism by which vascular networks prune redundant vessels and 190 
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adapt to the metabolic needs of the tissue[24]. Therefore, the establishment of functional blood 191 
flow in newly induced vascular structures was assessed by intravenous injection of biotinylated 192 
tomato lectin that binds the luminal surface of blood vessels and marks only vessels that are 193 
functionally perfused by systemic circulation[22]. Quantification of lectin perfusion showed that 194 
vessels in all conditions were well perfused (~ 70% of lectin+ endothelial structures), with the 195 
stiff gels showing a moderate reduction to ~ 50% (Figure 2l). This provided evidence that the 196 
RGD-modified CA gels support formation of fully functional vascular networks. Since Masson 197 
trichrome staining (Figure S2) revealed that hydrogels persist at the site of implantation even 198 
after 7 weeks, induce no foreign-body reaction as assessed by the absence of a collagenous 199 
capsule, and support efficient infiltration of host cells, the gels can be considered well 200 
integrated in muscle tissue. However, since SCID mice while having a fully functional innate 201 
immunity and inflammatory responses, lack B and T lymphocytes, the fate of the gels in 202 
immunologically fully competent subjects need to be further assessed in a future study. Taken 203 
together, these data suggest that: a) soft CA gel with mechanical properties similar to fibrin 204 
clot specifically promotes new vessel stabilization, yielding long-term persistent and mature 205 
(pericyte-associated) micro-vascular networks with the most optimal functional features of 206 
high density and branching complexity, and b) GF supplementation does not improve the long-207 
term angiogenic effect that are already imposed by the mechanical environment of the gels. 208 
Therefore, the observed effects may be attributed to the presence of RGD-modified CA gel 209 
environment.  210 
 211 
Circulating myeloid cells are enriched preferentially in soft hydrogel microenvironment:  212 
In order to elucidate a biological basis for our observations we explored two scenarios that 213 
could promote neo-vascularization and vessel stabilization namely: (1) differences in 214 
proliferation of endothelial cells in the gels, and/or (2) recruiting of circulating support cells. 215 
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We investigated endothelial proliferation by immunostaining for Ki67, which marks the 216 
nucleus of cells in all phases of the cell cycle (G1, S, G2, and M), excluding quiescent ones 217 
(G0)[25]. Quantification of Ki67+ endothelial nuclei showed that vascular networks in all gel 218 
compositions were essentially quiescent after 7 weeks, with at least 98% of ECs in G0 phase 219 
(Figure 2m-p and 2r). This is consistent with previous findings that in fully normal 220 
angiogenesis induced by VEGF 93% of ECs are in the G0 phase already after 1 week[26]. 221 
 222 
It has been shown that circulating myeloid cells can be recruited to sites of active angiogenesis 223 
and play a role in both maturation and stabilization of new vessels[27]. In particular, a specific 224 
population of CD11b+ monocytes called Neuropilin-Expressing Monocytes (NEM), which 225 
express Neuropilin-1 (Nrp1), a co-receptor for VEGF and Semaphorin3A co-receptor, has been 226 
recently found to accelerate new vessel stabilization by directly activating TGF-b1 227 
signaling[22], and indirectly by promoting pericyte recruitment through PDGF-BB secretion[28]. 228 
We therefore investigated whether the long-term stabilization of the capillary networks by the 229 
soft gel could relate to a differential enrichment of myeloid cells and specifically pro-230 
maturative CD11b+ monocytes. Immunofluorescent staining of cryo-sections of the gels two 231 
weeks following implantation revealed that the population of CD45+ myeloid cells was about 232 
40% higher in the softer versus the stiffer gel environment (476.9±37.7 vs 333.8±44.7 233 
cells/field, p<0.01; Figure 3a-c), but the enrichment of CD11b+ cells were similar in both gel 234 
environments (Figure 3d-f).  235 
 236 
Mechanically defined microenvironments sequester a unique CD11b+ sub-population 237 
expressing the stretch-activated cation channel Piezo-1: Mechanobiology, the paradigm in 238 
which mechanical stimuli are translated in biological signals through mechanotransduction 239 
elements, has a prominent role in the organization of cells[16] and interaction between cell 240 
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populations[29]. In addition to signaling via av integrins, a family of RGD-binding integrins[30], 241 
the stretch-activated ion channel Piezo-1[31] – an integrin activating transmembrane protein, 242 
has been shown to have critical role in angiogenesis[32]. Piezo-1 has also been implicated in 243 
cell-cell interactions[29] and has been shown to be inherently mechanosensitive[33]. Since the 244 
observed differences in the maturation and persistence of vessels are clearly correlated to the 245 
vastly differing stiffness of the two gels we inquired if the cells recruited into the gel 246 
environment express Piezo-1. Immunofluorescence staining identified for the first time a 247 
hitherto unknown population of CD11b+ myeloid cells expressing Piezo-1 (Figure 4a-b), 248 
which was significantly more frequently found in the softer than in the harder hydrogels, 249 
representing 93.1±1.4% of the total CD11b+ cells in the soft gels vs 71.8±2.4% in the stiff gels 250 
(p<0.0001; Figure 4c). Since CD11b is also expressed by neutrophils, which can also be 251 
recruited to sites of biomaterial implantation up to 2 weeks[34], we analyzed whether monocytes 252 
and/or neutrophils were present in the gels two weeks after implantation by H&E staining by 253 
exploiting their easily recognizable and characteristic nuclear morphologies. As shown in 254 
Figure S3, both cell types could be identified in gels of both stiffnesses. Based on this finding 255 
we further characterized the identity of the CD11b+/Piezo-1+ cells by staining for co-expression 256 
of CD11b with the specific markers CD115 for monocytes and Ly6G for neutrophils[35], and 257 
quantified their relative enrichment in the soft vs stiff gels. Interestingly, we identified novel 258 
Piezo-1+ sub-populations of both monocytes and neutrophils in both 0.5 and 5 kPa gels (Figure 259 
4d-g). However, quantification of the two populations revealed that only Piezo-1+ monocytes 260 
were significantly enriched by about 1.7-fold in soft vs hard gels (0.5 kPa=40.6±4.6% of total 261 
CD11b+ cells vs 5 kPa=24.4±2.6%, p<0.01; Figure 4h), whereas Piezo-1+ neutrophils were 262 
similarly frequent in the two conditions (0.5 kPa=25.4±3.9% vs 5 kPa=19.5±2.0%, p=n.s.; 263 
Figure 4h). 264 
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In order to ascertain if Piezo-1+ myeloid populations exist in the circulation and are enriched 265 
into the gels, or if Piezo-1 expression is induced upon exposure to the gel microenvironment, 266 
both mouse and human peripheral blood mononuclear cells were analyzed using flow 267 
cytometry. Human cells were also analyzed in order to establish the validity of the results in a 268 
translational perspective. A population of Piezo-1-expressing CD11b+ cells was identified in 269 
the circulation of both mouse and healthy human donors (Figure 4i-j), with surprisingly similar 270 
frequency, accounting for 35.0±2.2% and 35.1±9.1% of total CD11b+ cells respectively. 271 
However, further separation of the CD11b+ population between monocytes and neutrophils, 272 
based on mutually exclusive expression of CD115 and Ly6G (mouse) or CD14 and CD66b 273 
(human), showed that a Piezo-1+ sub-population could be found only in circulating monocytes, 274 
but not in neutrophils (Figure 4k-l), with similar frequency in both mouse and human blood 275 
(46.9±18.5% and 48.5±15.9% of total monocytes, respectively; Figure 4m-n). 276 
Therefore, these data suggest that a population of mechano-sensitive CD11b+/CD115+/Piezo1+ 277 
monocytes exist in normal circulation and that they can accumulate in CA hydrogels in 278 
differential manner based on their mechanical properties. The basis for this enrichment of 279 
CD11b+/Piezo-1+ population within CA gels could be either due to increased survival or 280 
retention or both and needs further investigation. On the other hand, mechanosensitive 281 
neutrophils could not be found in the circulation, but were observed in the CA gels, suggesting 282 
the possibility that Piezo-1 expression in this case may be mainly induced by the gel 283 
environment. The role of immune cells in regenerative medicine is an emerging theme. It has 284 
been recently shown that T helper 2 (Th2) lymphocytes, which comprise adaptive immunity 285 
play an important role in facilitating muscle tissue regeneration by ECM-based biomaterials[36]. 286 
Interestingly, our data show that the purely angiogenic effect of vessel stabilization by a 287 
mechanically defined environment does not require adaptive immunity, as this is lacking in the 288 
SCID mice. It is worth noting that in pulmonary inflammation recruitment of CD11b+ myeloid 289 
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cells have been found to be critical in the homing of activated Th2 lymphocytes and 290 
orchestration of an adaptive immune response[37]. Since the introduction of the gel in the 291 
muscle environment is bound to invoke an inflammatory response, the presence of CD11b+ 292 
cells could be a consequence of an inflammatory response. Considering these observations and 293 
the recently identified functions of CD11b+ monocytes in regulating the stabilization of newly 294 
induced vessels[22], the novel population of CD11b+/CD115+/Piezo1+ monocytes identified 295 
here may represent the link between the mechanics and angiogenic properties of hydrogels and 296 
represents a novel direction for future efforts in developing systems and pharmacological 297 
agents for therapeutic angiogenesis. 298 
 299 
Materials ad Methods 300 
Gels preparation and characterization 301 
Native agarose (1 g) (Merck, Darmstadt, Germany) was transferred into a 3-necked round-302 
bottom flask equipped with a mechanical stirrer and pH-meter (WTW, Weilheim, Germany), 303 
and dissolved in deionized water at a concentration of 1% w/v by heating to 90 °C. The flask 304 
was cooled down to 0 °C, using an ice bath, under vigorous mechanical stirring in order to 305 
prevent gelation of the agarose, and the reactor was charged with 99% (2,2,6,6-306 
tetramethylpiperidin-1-yl)oxyl (TEMPO) (20.6 mg, 0.16 mmol), NaBr (0.1 g, 0.9 mmol), and 307 
NaOCl (2.5 mL, 15% solution) all obtained from Sigma Aldrich (Steinheim, Germany). As the 308 
reaction occurs, the solution becomes acidic. The pH of the solution was maintained at 10.8 by 309 
dropwise addition of NaOH (0.1M) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 310 
throughout the duration of the reaction. The degree of carboxylation was back calculated by 311 
using the volumes of NaOH (0.1 M) solution added during the reaction. The reaction was 312 
quenched by the addition of NaBH4 (0.1 g) (Sigma-Aldrich Chemie GmbH, Steinheim, 313 
Germany), following which the solution was acidified to pH 8 (0.1mHCl) and stirred for 1 h. 314 
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The modified agarose was then precipitated by the sequential addition of NaCl (12 g, 0.2 mol) 315 
and ethanol (500 mL) (technical grade). The product was collected by vacuum filtration using 316 
a fritted glass funnel and then washed using ethanol (500 mL). The ethanol, catalyst, and salts 317 
were removed by extensive dialysis against water for 2 days with replacement of the water 318 
every 12 h. The modified agarose was then freeze-dried on a Beta 2−8 LD (Martin Christ 319 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) overnight to yield a white 320 
solid. The degree of carboxylation was verified by the appearance of peaks associated with 321 
aliphatic carboxylic acid groups via FTIR (KBr) (νc=o: 1750 cm−1) (Bruker Optics, Ettlingen, 322 
Germany) and NMR 300 Mhz (13C: 180 ppm) (Bruker BioSpin, Rheinstetten, Germany). The 323 
number average molecular weight of CA was determined as described earlier[16] and was in the 324 
range of 83,000 – 95,000. 325 
 326 
Carboxylated agarose mechanical properties  327 
Rheology experiments were performed with a Physica MCR 301 (Anton Paar, Wundschuh, 328 
Austria) equipped with a Peltier cell to control the temperature and the experiment was 329 
performed with a plate geometry PPR25 (Anton Paar, Wundschuh, Austria). Samples in 330 
deionized water were prepared by heating at 90 °C for 10 min until a clear solution was 331 
obtained. The liquid was then poured on the rheometer plate and the following sequence was 332 
used to determine the shear modulus: cool down from 80 °C to 5 °C in 30 min, 30 min 333 
equilibration at 5 °C to allow the gel to form, followed by heating to 37 °C and equilibration 334 
for 30 min prior to measuring G′ and G′′ by increasing the rotation frequency from 0.01 rad/s 335 
up to 10 rad/s with a 1% deformation. The G′ of the gel was determined at 1 Hz shear frequency.  336 
 337 
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Carboxylated agarose RGD functionalization 338 
Functionalization of CA with the RGDSP (Peptides International, Louisville, Kentucky, USA) 339 
peptide was performed using 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC) 340 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) coupling chemistry. CA was sterilized 341 
overnight in 70% ethanol, and the ethanol was re- moved by extensive dialysis against water. 342 
The sterile CA was freeze-dried overnight to yield a white solid. CA (30 mg, 0.25 µmol) was 343 
dissolved in MES sterile buffer (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and an 344 
excess EDC (210 mg, 1.3 mmol) was added and the solution stirred for 30 min. Following this 345 
the peptide was added (500 µg, 0.66 µmol for the CA-60 gels and 1 mg, 1.33 µmol for the gels) 346 
and the solution stirred for an additional 2 h at room temperature. Unreacted reagents were 347 
removed by dialysis against water. RGD incorporation was verified using elemental analysis 348 
Vario EL (Elementar Analysen systeme GmbH, Langenselbold, Germany) equipped with a 349 
thermal conductivity detector and an adsorption column for CO2 at 110 °C and H2O at 150 °C. 350 
All samples were accurately weighed to 3 mg before measurements and the percentage of 351 
nitrogen was used to calculate the peptide attachment. It was found that 11.6 ± 0.9 % of the 352 
repeat units where functionalized on both CA-28 and CA-60. 353 
 354 
Gels implantation in vivo 355 
Gels were implanted into 10-15 week old immune-deficient SCID CB.17 mice (Charles River 356 
Laboratories, Sulzfeld, Germany). Animals were treated in accordance with Swiss Federal 357 
guidelines for animal welfare, and the study protocol was approved by the Veterinary Office 358 
of the Canton of Basel-Stadt (Basel, Switzerland; Permit 2071). Gels were pre-loaded in 1 ml 359 
syringes and kept on ice (~ 4 °C) until injection. Fifty µl of cold PBS (Sigma-Aldrich Chemie 360 
GmbH, Steinheim, Germany) followed by 50 µl of cooled gels were implanted along the 361 
midline of both the medialis and lateralis portions of Gastrocnemius leg muscle in a standard 362 
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caudo-rostral direction, using a syringe with a 291/2G needle (Becton Dickinson, Allschwil, 363 
Switzerland). Gels supplemented with growth factors were loaded with 50 ng/mL of each 364 
vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2) both from R&D 365 
Systems (Minneapolis, USA) and phorbol-12-myristate 13-acetate (PMA) from Sigma Aldrich 366 
(Munich, Germany). 367 
 368 
Tissue staining and microscopy 369 
For the studies performed on frozen tissue sections, mice were anesthetized and the tissues 370 
were fixed by vascular perfusion of 1% paraformaldehyde in PBS pH 7.4 for 4 minutes under 371 
120 mm/Hg of pressure. GC muscles were harvested, post fixed in 0.5% paraformaldehyde in 372 
PBS for 2 hours, cryo-protected in 30% sucrose in PBS overnight at 4°C, embedded in OCT 373 
compound (CellPath, Newtown, Powys, UK), frozen in freezing isopentane and cryosectioned. 374 
Cryosections were obtained systematically in a caudo-rostral direction throughout the whole 375 
sample, maintaining an anatomically standardized orientation, and analyses were performed 376 
on all sections representing the complete area of implantation. Tissue sections (30 µm) were 377 
stained with Hematoxylin and eosin (H&E) and in addition, the gel biocompatibility was 378 
examined with Masson trichrome staining (Réactifs RAL, Martillac, France), performed 379 
according to manufacturer's instructions. For immunofluorescent staining of neighboring 30 380 
µm thick longitudinal cryosections, the sections were blocked with PBS 0.1% triton 381 
supplemented with 5% normal goat or donkey serum and 2% BSA (all reagents from Sigma-382 
Aldrich Chemie GmbH, Steinheim, Germany) for 1 hour. The slides were then incubated for 383 
1.5 hour at room temperature with the following primary antibodies and dilutions: rat anti-384 
mouse PECAM-1 (clone MEC 13.3, BD Biosciences, Basel, Switzerland) at 1:100 or hamster 385 
monoclonal anti-mouse CD31 (clone 2H8, Millipore, Merck, Germany) at 1:200; mouse anti-386 
mouse/human a-SMA (clone 1A4, MP Biomedicals, Basel, Switzerland) at 1:400; anti-mouse 387 
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NG2 (Chemicon International, Hampshire, UK) at 1:200; rabbit anti-Ki67 (Abcam, 388 
Cambridge, UK) at 1:100; rat monoclonal anti-CD11b (clone M1/70, Abcam, Cambridge, UK) 389 
at 1:100; rat anti-mouse CD45 (PE conjugated, clone 30 F11, BD Biosciences, Basel, 390 
Switzerland) at 1:400. Negative controls lacking primary antibody were always performed. 391 
Sections were rinsed in PBS 0.1% triton and then incubated for 1.5 hour at room temperature 392 
with fluorescently labeled secondary antibodies (Invitrogen, Basel, Switzerland) diluted at 393 
1:200. The slides were then rinsed and mounted. 394 
Piezo1 staining immunohistochemistry experiments were performed on Ventana 395 
DiscoveryUltra instrument (Roche Diagnostics, Manheim, Germany) by using the procedure 396 
RUO Discovery Universal instead. Cryosections were fixed for 12 minutes with 4% 397 
paraformaldehyde followed by 1 hour incubation at 37°C with rat anti-CD11b (1:100), alone 398 
or together with rat monoclonal anti-CD115 (clone CSF-1R, Biolegend, London, UK) at 1:100 399 
or rat monoclonal anti-Ly6G (clone 1A8, Biolegend, London, UK) at 1:100, and 32 minutes 400 
incubation at 37°C with fluorescently labeled anti-rat IgG1 or IgG2a secondary antibodies used 401 
at 1:100 (ThermoFisher Scientific, Basel, Switzerland). Next, after an antibody denaturation 402 
step, sections were pre-treated for 16 minutes with Cell Conditioning Solution (CC1) (Roche 403 
Diagnostics, Mannheim). Rabbit anti-Piezo1 (Proteintech, Manchester, UK) diluted at 1:500 404 
was then incubated for 32 minutes at 37°C and detected with the secondary antibody 405 
(ImmPRESS reagent kit peroxidase anti-rabbit Ig MP-7401, Vector Laboratories, Burlingame, 406 
CA, USA) applied manually (200 µl) for 32 minutes. Discovery Rhodamine (Roche 407 
Diagnostics, Mannheim) applied for 12 minutes was used for the detection. To study vessel 408 
perfusion, 100 µg of biotinylated Lycopersicon esculentum (tomato) lectin (Vector 409 
Laboratories, Burlingame, CA, USA) was dissolved in 100 µl, which binds the luminal surface 410 
of all blood vessels, and injected intravenously through the femoral vein. After four minutes 411 
the thoracic cavity was opened and the tissues were fixed by perfusing the animal with 1% 412 
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paraldehyde and leg muscle were collected and processed as described above. Fluorescently 413 
labeled Streptavidin (eBioscience, Vienna, Austria) at 1:200 was used to visualize the perfused 414 
vasculature. Frozen sections were mounted with Faramount Aqueous Mounting Medium 415 
(Dako, Agilent Technologies, Basel, Switzerland), and fluorescence images were taken with 416 
40x objectives on a Carl Zeiss LSM710 3-laser scanning confocal microscope (Carl Zeiss, 417 
Feldbach, Switzerland) or with a 20X objective on an Olympus BX61 microscope (Olympus, 418 
Volketswil, Switzerland). All Image analysis were performed with either Cell Sense software 419 
(Olympus, Volketswil, Switzerland) or Imaris 7.6.5 software (Bitplane, Zürich, Switzerland) 420 
on fluorescence images acquired with a 20X objective on an Olympus BX61 microscope or 421 
with a 40x objective on a Carl Zeiss LSM710 3-laser scanning confocal microscope. 422 
 423 
Histological analysis 424 
The quantification of vessel length density (VLD) and vessel perfusion was performed on 425 
sections of leg muscles harvested after intravascular staining with biotinylated lectin and 426 
fluorescently labeled streptavidin, as described above. After co-staining with a fluorescent anti-427 
CD31 antibody, VLD was measured on 6-10 randomly acquired fields per leg and 4 muscles 428 
per group (n = 4) by tracing the total length of vessels in the fields and dividing it by the area 429 
of the fields. The total lengths of lectin-positive and CD31-positive vascular structures in each 430 
field were traced independently and the vessel perfusion index was calculated as the ratio 431 
between the two values. The degree of branching of a vascular network depends on the total 432 
number of branch points in relation to the total amount of vascularity. Therefore, the degree of 433 
vessel branching was quantified by counting the number of branch points (n) in all 434 
representative fields per muscles and dividing the corresponding total vessel length by n+1, 435 
yielding the average vascular segment length. Vessel diameters were measured by overlaying 436 
a captured microscopic image with a square grid. Squares were chosen at random, and the 437 
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diameter of each vessel (if any) in the center of selected squares was measured. Two to five 438 
hundred total vessel diameter measurements were obtained from 4 muscles per each group (n 439 
= 4). The quantification of pericyte coverage was performed on sections of leg muscles after 440 
immunostaining for endothelium (CD31) and pericytes (NG2). The total lengths of CD31- and 441 
NG2-positive structures were measured by a blinded investigator and the pericyte coverage 442 
index was calculated as the ratio between the two values. Ki67+ endothelial cells (ECs) were 443 
quantified from the total number of ECs (260-890 total ECs were counted per condition at 7 444 
weeks post gel implantation) in vascular structures visible in each of 3-5 fields, in each area of 445 
effect. 10 areas with a clear angiogenic effect were analyzed per group. The quantification of 446 
leukocytes (CD45) and monocyte (CD11b) were performed on 7 random areas per muscle (n 447 
= 4) per group by counting them and normalizing to the absolute number of CD45+ and CD11b+ 448 
cells with area. (9000-1400 total CD45+ cells and 5000-6000 total CD11+ cells were counted 449 
per condition at 2 weeks post gel implantation). The quantification of Piezo1+/CD11b+ cells 450 
was performed on 7-10 random areas per muscle (n = 4 samples/group) after immunostaining 451 
for CD11b (700-800 total CD11+ cells were counted per condition at 2 weeks post gel 452 
implantation). The quantification of Piezo1+/CD11b+/ CD115+ monocytes and 453 
Piezo1+/CD11b+/Ly6G+ neutrophils was performed on 5-7 random areas per muscle (n = 4 454 
samples/group) after immunostaining for CD11b, CD115 or Ly6G (480-900 total CD11b+ cells 455 
were counted per condition at 2 weeks post gel implantation). 456 
All Image measurements were performed with both Cell Sense software (Olympus, Volketswil, 457 
Switzerland) and Imaris 7.6.5 software on fluorescence images acquired with a 20X objective 458 
on an Olympus BX61 microscope or with a 40x objective on a Carl Zeiss LSM710 3-laser 459 
scanning confocal microscope. 460 
 461 
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Blood cell analysis by FACS 462 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from the whole blood of 4 463 
immune-deficient SCID CB.17 mice (Charles River Laboratories, Sulzfeld, Germany) and 3 464 
human healthy donor using a red blood cell lysis buffer (RBC Lysis Buffer, Invitrogen, Basel, 465 
Switzerland). After lysis, the PBMCs were stained with APC-anti-human CD11b (clone 466 
CBRM1/5, Biolegend, Basel, Switzerland) at 1:100, PE-anti-human CD66b (clone G10F5, 467 
Biolegend, Basel, Switzerland) at 1:100 and BV711-anti-human CD14 (clone M5E2, 468 
Biolegend, Basel, Switzerland) at 1:100, or BV605-anti-mouse-CD11b (clone M1/70, 469 
Biolegend, Basel, Switzerland) at 1:100, PE-anti-mouse-Ly6G (clone 1A8, BD Biosciences, 470 
Basel, Switzerland) at 1:100, APC-anti-mouse-CD115 (clone AFS98, BD Biosciences, Basel, 471 
Switzerland) at 1:100. A cross-reacting anti-human Piezo1 (Abcam, Cambridge, UK) was used 472 
at 1:500 for both human and mouse cells. An Alexa Fluor 488-labeled secondary antibody was 473 
used to detect Piezo1 (Invitrogen, Basel, Switzerland) at 1:200. Samples were acquired by LSR 474 
Fortessa (BD Biosciences, Basel, Switzerland), and data analyzed by FlowJo software (Tree 475 
Star, Ashland, OR, USA). 476 
 477 
Statistical analysis 478 
Data are presented as mean±standard error. All quantifications have been performed by blinded 479 
investigators to avoid bias. The significance of differences was assessed with the GraphPad 480 
Prism 7.03 software (GraphPad Software). The normal distribution of all data sets was tested 481 
and, depending on the results, multiple comparisons were performed with the parametric 1-482 
way analysis of variance (ANOVA) followed by the Sidak test for multiple comparisons, or 483 
with the non-parametric Kruskal-Wallis test followed by Dunn’s post-test, while single 484 
comparisons were analyzed with the non-parametric Mann-Whitney test or the parametric 485 
unpaired t-test. 486 
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Figures 584 
 585 
Figure 1. RGD functionalized carboxylated agarose hydrogels induce angiogenesis. a-d Frozen 586 
sections of GC muscles, implanted with distinct hydrogel compositions and harvested 2 weeks later, 587 
were stained for hematoxylin/eosin and (e-h) immunostained against CD31 (endothelial cells, red), 588 
NG2 (pericytes, green), a-SMA (smooth muscle cells, cyan). Black arrows in a-d indicate the injected 589 
gels. Quantification of vessel morphology: Vessel diameters (i) and vascular segment length (j) were 590 
quantified in the same areas within the hydrogels two weeks post implantation: VLD = vessel length 591 
density, is expressed as millimeters of vessel length per square millimeter of area of effect (mm/mm2); 592 
the segment length is expressed as µm of vessel length between 2 consecutive branch points (k). 593 
GF=Growth Factors. All data sets represent mean values ± SEM with all individual measurements 594 
shown; * p<0.05, ** p<0.01 by Kruskal-Wallis test; n= 4 independent muscles per each group. Scale 595 
bars = 1 mm in all HE-stained panels. Scale bars = 20 µm in all immunofluorescence-stained panels. 596 
 597 
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 598 
Figure 2. Soft RGD-functionalized carboxylated agarose supports stable capillaries. a-h 599 
Immunofluorescence staining of endothelium (CD31, in red), pericytes (NG2, in green), smooth muscle 600 
cell (α-SMA, in cyan) on frozen sections of leg skeletal muscles of mice injected with distinct hydrogel 601 
compositions and sacrificed 7 weeks later. Higher-magnification panels (e-h) show the tight association 602 
between pericytes and endothelium of vessels in soft gels (g-h). i-l VLD, vascular segment length, 603 
vessel diameters and perfusion index were quantified in the same areas within the hydrogels. 604 
GF=Growth Factors. All data sets represent mean values ± SEM with all individual measurements 605 
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shown; * p<0.05, ** p<0.01, *** p<0.001 and ****p<0.0001 by Kruskal-Wallis test; n= 4 independent 606 
muscles per each group.  m-p, r Endothelial proliferation was assessed by quantifying the percentage 607 
of endothelial cells positive for Ki67 (r) by immunofluorescence staining on frozen muscle sections 608 
(m-p), n= 4 independent muscles per group. q Pericyte coverage was quantified in areas implanted with 609 
each hydrogel. Soft gels displayed a marked increase in pericyte coverage compared to stiff gels. Data 610 
represent mean values ± SEM; ** p<0.01 and *** p<0.001 by Kruskal-Wallis test. n = 4 independent 611 
muscles per each group. Scale bars = 20 µm in all immunofluorescence-stained panels. 612 
 613 
 614 
Figure 3. RGD Functionalized carboxylated agarose recruit myeloid cells. a, b, d, e 615 
Immunofluorescence staining of endothelial cells (CD31, in green), leukocyte (CD45, in red) and 616 
monocytes (CD11b, in red) on cryosections of limb muscles 2 week after injection with 5 kPa and 0.5 617 
kPa hydrogel compositions. Scale bar= 20µm in all panels. c, f Quantification of the number of CD45+ 618 
and CD11b+ cells recruited into the implanted hydrogel. All data sets represent mean values ± SEM 619 
with all individual measurements shown; ** p<0.01, by Mann-Whitney test; n= 4 independent muscles 620 
per each group. 621 
622 
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 623 
 624 
Figure 4. CD11b+/CD115+/Piezo-1+ monocytes are enriched in soft RGD-functionalized 625 
carboxylated agarose microenvironment. (a-b) Immunofluorescence staining of CD11b+ cells 626 
(in red) and of PIEZO-1+ cells (in light blue) on cryosections of limb muscles 2 weeks after injection 627 
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with 5 kPa and 0.5 kPa hydrogel compositions. Scale bar= 20µm in all panels. (c) Quantification of 628 
CD11b+/Piezo1+ cells in sites within the implanted gels (% of total CD11b+ cells). (d-g) 629 
Immunofluorescence staining of CD11b (in red), CD115 (in green), Ly6G (in green) and PIEZO-1 (in 630 
white) on cryosections of limb muscles. White arrows and arrowheads in panels d and e indicate Piezo-631 
1+ and Piezo-1- monocytes (CD11b+/CD115+) respectively. White arrows and arrowheads in panels f 632 
and g similarly indicate Piezo-1+ and Piezo-1- neutrophils (CD11b+/Ly6G+) respectively. Scale bar= 633 
20µm in all panels. (h) Quantification of Piezo1+ monocytes and Piezo1+ neutrophils in sites within the 634 
implanted gels (% of total CD11b+ cells). (i-j) Circulating Piezo-1+/CD11b+ cells were identified in 635 
both mouse and human blood by FACS. (k) Detection of circulating Piezo-1+ monocytes 636 
(CD11b+/CD115+/Ly6G-) and neutrophils (CD11b+/CD115-/Ly6G+) in mouse blood. (l) Detection of 637 
circulating Piezo-1+ monocytes (CD11b+/CD14+/CD66b-) and neutrophils (CD11b+/CD14-/CD66b+) in 638 
human blood. (m-n) Quantification of circulating Piezo-1+ monocytes and Piezo-1+ neutrophils in 639 
mouse and human blood respectively (% of total monocytes or neutrophils). All data sets represent 640 
mean values ± SEM with all individual measurements shown; **** p<0.0001 and ** p<0.01 by 641 
unpaired t-test (c) or by Mann-Whitney test (h, m and n). FACS experiment: n= 4 mice and n= 3 human 642 
donors. 643 
  644 
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 645 
Supplemental Figure S1. Matrigel is not necessary to increase the vascular ingrowth inside the 646 
hydrogels. (a-d) Hind limb murine muscles were implanted with distinct hydrogel + Matrigel 647 
compositions. Two weeks later frozen sections were stained with hematoxylin/eosin (a, c) or 648 
immunostained against CD31 (endothelial cells, red), NG2 (pericytes, green) and a-SMA (smooth 649 
muscle cells, cyan) (b, d). Black arrows in a and c indicate the injected gels. (e-g) Quantification of 650 
vessel morphology: Vessel diameters (e), amount of angiogenesis (f) and vascular segment length (g) 651 
were quantified in the same areas within the hydrogels: VLD = vessel length density. All data sets 652 
represent mean values ± SEM with all individual measurements shown; ****p<0.0001 by Kruskal-653 
Wallis test; n= 4 independent muscles per each group. Scale bars = 1 mm in all HE-stained panels; 20 654 
µm in all immunofluorescence-stained panels. 655 
  656 
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 657 
Supplemental Figure S2.  RGD functionalized carboxylated agarose hydrogels are well 658 
integrated in muscle tissue. a-h Frozen sections of Gastrocnemius muscles implanted with 659 
distinct hydrogel compositions were stained for Masson trichrome staining. Two weeks (a-d) 660 
and 7 weeks (e-h) after implantation all hydrogels compositions were clearly persistent and 661 
well-integrated in muscle tissue. Lower panels represent higher-magnification images of the 662 
upper panels. n=4 independent muscles/group. Scale bars = 1 mm (low-magnification panels) 663 
and 50 µm (high-magnification panels). 664 
  665 
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 666 
Supplemental Figure S3. Monocytes and neutrophils in sites within the implanted gels. 667 
H&E staining of cryosections of limb muscles 2 week after injection with 5 kPa (a-b) and 0.5 kPa 668 
hydrogel compositions (c-d). White arrows and arrowheads in high magnification panels (b and 669 
d) indicate monocytes and neutrophils, respectively. Scale bar = 20µm in all panels. 670 
 671 
